Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim, triggering a 4.0 million euro payment for the transition of an oncology molecule into preclinical development.
Dr. Mario Polywka, chief operating officer of Evotec said, "This is the 21st milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into preclinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec's overall strategy of building up a pipeline of assets of which we have interest in future upside."
In 2004, the companies entered into a multi-year, multi-target drug discovery alliance to identify and develop preclinical candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.
Evotec Earns Boehringer Milestone
By Kristin Brooks
Published December 10, 2013
blog comments powered by Disqus